Yu Shyr has published more than 500 peer-reviewed papers (h-index=115) on statistical and bioinformatic methods, techniques for multivariate data analysis, adaptive clinical trials, nonparametric smoothing methods for longitudinal binary data, and more, as well as collaborative research papers on cancer biology, epidemiology, and clinical trials; diabetes and nephrology; orthopedics; immunology, cardiology; and other fields. As a data scientist, he is known for his contributions to protocols and methodologies critical for clinical trial design, multidimensional genomic data processing, and the collection and analysis of genomic sequencing data. He is associate editor for statistics at JAMA Oncology and serves on more than a dozen external advisory boards, as well as the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee, and principal investigator for Barrett’s Esophagus Translational Research Network Coordinating Center (BETRNetCC).

Joakim Lundeberg PhD, Professor in Molecular Biotechnology since 2000. JL was one of the co-founders of Science for Life Laboratory Sweden in 2010, a national and multi-university effort in large scale life sciences providing access to infrastructures such as genomics, proteomics, imaging, metabolomics and drug development. There are approximately 700 research scientists embedded in the infrastructure performing independent research. Dr Lundeberg has during the most recent years focused spatial transcriptomics technology, that enables detailed description of gene expression patterns in tissue sections. The spatially resolved transcriptomics was announced to be the Method of Year 2020 by Nature Methods and spatial transcriptomics is commercially available from 10X Genomics Inc as Visium. Dr Lundeberg has several publications demonstrating the development of the technology but also examples on the impact of the technology in biology. The current research focus on expanding the spatial modalities, developing new software tools and applications in human cell atlas, neurology and cancer.

The laboratory of kidney omics and metabolism, led by Markus Rinschen, investigates the molecular processes that lead to chronic kidney disease. One out of ten people suffer from chronic kidney disease, an unmet burden to individuals and societies. Common causes are hypertension, diabetes, or genetic or environmental factors. Our key hypothesis is that understanding of molecular tissue pathophysiology and metabolism provides new avenues to treat and intervene with progression of chronic kidney disease. To approach this, we use a wide array of metabolic, mass spectrometric and bioinformatics tools, and integrate and benchmark big data sets with physiological function. Our results have unraveled new omics-guided targets for kidney disease in mice and men, in particular in the area of glomerular kidney disease. Dr. Rinschen is a Novo Nordisk Foundation Young Investigator and serves Associate Editor for the Journal of American Society of Nephrology and Physiol Genomics.

Chao-Jung Chen received his Ph.D. degrees from National Taiwan University in 2007. He has a post-doctoral training in proteomic and metabolomic researches at Academia Sinica. In 2010, He joined in China Medical University (CMU) and China Medical University Hospital (CMUH), Taiwan as a faculty member. He is now in charge of the proteomics core lab in CMU and CMUH. His current research involves novel MS-based method developement, protein/metobolite biomarker discovery, developement of platform for rapid screening of active compounds in Chinese medicine. He has been the board member of Taiwan Society for Mass Spectrometry (TSMS) since 2015 and the board member of Taiwan Proteomics Society(TPS) since 2021.

Dr. Charles Lai is an Associate Research Fellow at the Institute of Atomic and Molecular Sciences, Academia Sinica, Taiwan. Dr. Lai received his BSc and PhD from the University of British Columbia, Canada. His research focuses on developing molecular bioimaging tools to investigate biological phenomena in vivo, including nanosized bioparticles (i.e., extracellular vesicles [EVs]; exosomes) and DNA repairs. His recent research identified dynamic organotropism of cancer EVs, as well as non-invasively tracked DNA repair dynamics under genome-editing and anti-cancer treatments. His work has been published in top tier journals such as Nucleic Acids Research, Advanced Sciences, Nature Protocols, ACS Nano, and Nature Communications. He is the recipient of multiple awards, including International Outstanding Young Scholars Research Grant (National Science and Technology Council [NSTC], Taiwan), Excellent Young Scholar Research Grant (NSTC), Career Development Award (Academia Sinica, Taiwan), Young Scientist Award (YungShin Tien Te Lee Biomedical Foundation, Taiwan), and Young Scholar Innovation Award (Foundation for the Advancement of Outstanding Scholarship, Taiwan).

Dr. Josh Wu has developed interdisciplinary approaches to study the mechanobiology for tissue engineering and regenerative medicine. In these investigations, Wu has integrated multi-disciplinary researches for elucidating (1) microenvironmental cues for stem cell differentiation and therapeutic application to rescue the nervous and vascular systems; (2) effects of flow-induced shear stress in venous endothelial cells (ECs) and hence their signaling for pathological modulations in vein graft diseases; (3) smart system and non-invasive approaches to monitor wound injury and promote regeneration; (4) micro/nano manufacture of cellular chip for stem cell differentiation and cell-cell interactions; (5) certification and dynamics of exosome/extracellular vesicles for neurovascular diseases and stem cells. These results have provided new platforms to understand the cell-cell interaction, pathological progression of neuronal and vascular diseases, and potential therapeutic approach of cell-based therapy.

Dr. Chao graduated from medical school (National Taiwan University College of Medicine) in 2005, and completed his Toxicology PhD program in 2017. He mainly focuses on geriatric nephrology, circulatory microRNAs, and vascular biology, particularly microRNAs in vascular calcification. He has published more than 150 SCI-indexed papers across experimental and clinical nephrology and vascular medicine, including Kidney International, Cardiovascular Research, Arteriosclerosis Thrombosis Vascular Biology, etc. He now serves as an associate editor in BMC Geriatrics and Frontiers in Medicine.

Dr. Jou is currently a doctoral candidate in the International College of Semiconductor Technology, National Yang Ming Chiao Tung University (NYCU). In the past six years, Dr. Jou has been committed to the research of microfluidic chips and circulating rare cells. In addition to his primary roles in the Hospital, he is also a principal investigator of the circulating tumor cell and genetic laboratory in TAH, in which he leads a team to provide supports for clinical research and the development of precision medicine. Dr. Jou is also a Supervisor Member of Taiwan Precision Medicine Society.

Dr. Hidetoshi Tahara is Vice President (Academia-Government-Industry Collaboration) and Professor of the Department of Cellular and Molecular Biology, Hiroshima University.He has been researching cell senescence, immortalization, and canceration, as well as telomeres and microRNAs. Recently, he has succeeded in developing nucleic acid medicine using microRNA, started a first-in-human doctor-initiated clinical trial targeting malignant pleural mesothelioma in January of this year, and administered it to humans. He has established a new start-up called PURMX Therapeutics, Inc. and is trying to implement drug discovery using microRNA. He has won the special award for EY Entrepreneur of The Year 2022 Japan and the special award for Academic Startups 2022. He has launched “Hiroshima Love it Consortium” last year and started a healthy longevity project to coordinate with the health longevity agenda. He aims it to be a consortium where everyone who gathers can enjoy win-win through innovation in industry-academia collaboration.

Dr. Hsiao-Han Chang is an Associate Professor at the Institute of Bioinformatics and Structural Biology, National Tsing Hua University (NTHU), Taiwan. Dr. Chang received her Ph.D. in Organismic and Evolutionary Biology and performed her postdoctoral research in the Department of Epidemiology at Harvard University. Dr. Chang’s research uses approaches from genomics, bioinformatics, statistics, and mathematical modeling to infer the spread of infectious diseases and understand pathogen evolution.

Dr. Hsin-Yi Chang studies fundamental biological questions by mass spectrometry-driven proteomics and metabolomics including quantitative proteomics, post-translational modifications (PTMs), protein-protein interactome, subcellular proteomics, and targeted/untargeted metabolomics. Currently, her research interest is to map the scope of the critical molecules and post-translational modifications for determining the thermogenesis process in white adipocytes. She is also interested in developing new methods in clinical proteomics in cancer research, especially focus on methods to measure PTM modifier/eraser activity, to determine active ligand-receptor interaction, and to identify bona fide drug targets. This leads her research focusing on big data analysis to integrate multi-layer omic data toward translational medicine.

Dr. Hurng-Yi Wang is a Professor of Graduate Institute of Clinical Medicine at the National Taiwan University (NTU), Taiwan. Dr. Wang received his Ph.D degree from the National Taiwan Normal University. The researches in Dr. Wang’s lab are concentrated on molecular evolution and population genetics. Currently, there are two major domains in his lab. The first one is virus related research. He focuses on patterns of viral diversity change within host, rate of viral evolution, and interaction between pathogen and host. The second domain is to understand the mechanisms that drive population differentiation including nature as well as tumor cell populations.

I am a population geneticist interested in knowing about the ecology and evolution of eukaryotic microorganisms in nature. I received my PhD training in the UK looking at how population genetics theories can be used to infer frequency of sex of Saccharomyces paradoxus in nature. Since starting my lab at Biodiversity Research Center, Academia Sinica Taiwan in 2015 I was interested in knowing the diversity of Saccharomyces here. East Asia is now known to be the geographic birthplace of S. cerevisiae, and it harbors the species’ most divergent natural lineage; here at the MOPM meeting I will present how we leveraged a six-year deep sampling of the broad-leaf forests across the continental island of Taiwan to probe S. cerevisiae’s ancestral species diversity.

We have extensively explored new models of computational systems biology and computer-aided drug design to study fundamental theories of molecular interactions (e.g., Molecular Interaction Family) in cells. Our goal is to study drug-protein-pathway-cellular processes-disease relationships, and to establish the links from basic research to translational medicine. To achieve these goals, our team has been committed to integrate artificial intelligence, big data, physico-chemical concepts, and biology for exploring relationships among "molecular interactions", "cell behavior" and "drug discovery principles". To validate our models, we have rigorously collaborated with biological/clinical teams and their bioassay/clinical results support and demonstrate that our models are able to address the challenges and achieve our goals. We have continuously collaborated with researchers from various universities and institutes like NHRI, Academic Sinica, research hospitals (e.g., NTUH, TMU, and KMU) and international institutes (e.g., Kyoto University and Harvard University) for resolving unmet clinical needs and important biological issues.

Dr. Jung-Hsin Lin is a Research Fellow at the Research Center for Applied Sciences, Academia Sinica, Taiwan. Dr. Lin did his Ph.D in Biophysics in Forschungszentrum Jülich, Germany, and he worked as Bioinformatics Specialist at the Howard Hughes Medical Institute at University of California, San Diego, U.S.A. Dr. Lin had been involved mainly in developing novel methods for computational drug discovery for the past ~20 years. He is the inventor of 17 patents for the new drugs discovered from his collaborative teams. Two series of drug candidates on neurodegenerative diseases and cancer treatment were exclusively licensed to the companies in Taiwan in 2015 and 2016, respectively. He has recently also set up a laboratory for protein expression and purification, and has already carried out some cryo-EM experiments for determining membrane protein structures and NMR experiments for structure determination and dynamics characterization.

The major professional expertise of Dr. Hsiao is molecular endocrinology and tumor biology with special focus on epigenetic regulatory mechanisms and noncoding RNAs. The current directions of his research focus on the characterization of biological functions, pathological roles of circular RNAs, and the mechanisms underlying the regulation of circRNA expression using integrated analyses of bioinformatics, proteomics, molecular biology, clinical profiling and animal experiments in the models of endocrine-related diseases and colorectal cancer.

Computational structural biologist Lee-Wei Yang is currently a Full Professor and the Director of IBSB, CLSM and BAI PhD Program in NTHU. Dr Yang was trained in chemical/biochemical engineering (BS@NTU and then Master@NTHU), obtained his PhD from the School of Medicine, University of Pittsburgh under the supervision of Dr Ivet Bahar (a NAS member), and received subsequent postdoctoral trainings in University of Tokyo (2006-2009; supervised by Profs Nobuhiro Go and Akio Kitao) and Harvard University (2010-2011; supervised by Dr Eugene Shakhnovich). He is an Honorary Professor of University of Liverpool (2018-2022) supervising dual PhD program, a visiting professor in University of Osaka (2018) and University of Pittsburgh (2022). Dr Yang received Wu, Ta-You Memorial Award during his service as a program coordinator in National Center for Theoretical Sciences (Physics Division; 2017-2020) and Division Director of International Students, Office of Global Affairs, NTHU (2016-2019). Dr Yang has a long-term research focus on protein dynamics and coined the decade long bioinformatics/biophysics efforts as “DynOmics”. He demonstrated biomolecular functions as stereochemistry facilitated by an action of protein dynamics and the importance of dynamics in drug design. Dr Yang is an Associate Editor of Biophysics and Physicobiology and Editor of a Special Issue in IJMS.

Professor Tang is an internationally recognized expert in mechanobiology, tissue engineering and regenerative Medicine. After his MD at Taipei Medical University (1980) and PhD in Physiology at the University of Michigan Medical Center, Ann Arbor (1987), he conducted postdocs at the University of Michigan and University of Southern California Medical School. He returned to the National Cheng Kung University Medical College, Tainan, Taiwan in 1990 and became Associate and then Full Professor in the Department of Physiology. In 2001, he became Executive Vice Dean, and Distinguished Professor at the National Cheng Kung University Medical College. He was Vice President for Academic Affairs of National Cheng Kung University (2007-2011) and President of the Tunghai University, Taichung, Taiwan (2013-2016) before being recruited as the Director of the International Center for Wound Repair and Regeneration (iWRR), National Cheng Kung University. Professor Tang published over 130 articles in internationally leading journals. He received numerous awards and international recognition for his ground-breaking discoveries, especially on the influence of stiffness on cellular physiology in epithelial cells and fibroblasts and mechanobiology of cancer cells.

Dr. Mingzi Zhang received her BSc in Bacteriology from the University of Wisconsin-Madison and her PhD in Chemical Biology from The Rockefeller University. She is interested in the study of cellular metabolism to identify novel therapeutic targets and bioactive molecules. By developing novel chemical probes and chemoproteomics strategies, her research group seeks to explore the druggability landscape of the human proteome in different disease contexts.

Prof. Muh-Hwa Yang majors research interest is to study the pleiotropic effects of epithelial-mesenchymal transition (EMT) during cancer metastasis. EMT is a major mechanism in development and cancer metastasis. However, the knowledge about EMT beyond the induction of cellular disaggregation and migration is limited. Prof. Yang’s lab focuses on the multifaceted role of the EMT during cancer progression, including the induction of cancer stemness (Nat Cell Biol 2010, Cell Rep 2016, Theranostics 2020), mesenchymal movement in 3-dimensional culture system (Nat Cell Biol 2012; Oncogene 2016), symmetrical division of cancer stem cells (Nat Cell Biol 2014), modulation of cancer cytokinome (Cancer Cell 2014) and exosomes (Neoplasia 2018; J Hemetol Oncol 2019; Int J Cancer 2019), and collective cell migration (Nat Cell Biol 2019). Prof. Yang also delineate the role of tumor-associated macrophages in regulating epithelial plasticity for tumor colonization (Nat Commun 2018). In addition to basic cancer biology, Prof. Yang was trained as a hematologist-oncologist and I am also interested in the field of clinical cancer treatment. Prof. Yang majors experience is in the treatment of head and neck cancer, which is one of the most devastating male cancers in Taiwan due to habitual betel nut consumption. Prof. Yang also have the translational researches regarding the therapeutic resistance in head and neck cancer (Clin Cancer Res 2010; Clin Cancer Res 2017) and multikinase inhibitors for modulating microenvironments to enhance response (J Immunother Cancer 2021).

Dr. Pei-Lung Chen is a physician scientist with the expertise in genetics/genomics and endocrinology. He received his M.D. degree from National Taiwan University, and Ph.D. degree from Hopkins University School of Medicine. Throughout his career, he has been focusing on identification of the genes/variants responsible for various human diseases, namely “genetic mapping”. Next-generation sequencing (NGS), human leukocyte antigen (HLA) genotyping, various other genotyping technologies, model organisms and bioinformatics are the tools that Dr. Chen uses extensively. Dr. Chen has been taking genetic approaches to study several complex or Mendelian diseases. In recent years, Dr. Chen has been devoted to immunogenomics, pharmacogenomics and precision medicine.

Dr. Shih-Cheng Chen has multi-disciplinary training with over 12 years’ experience in academic/industrial/administrative perspectives in the field of biomedical science. He was particularly devoted to RNA biology since his discovery of several conserved RNA structures in many RNA viruses and mammalian mRNAs during 2005-2010. Later he focused on the functional relevance of newly identified RNA elements to the regulation of translation and/or encapsidation. Recently, comprehensive structural phylogenetic analysis of coronaviruses revealed highly conserved structural motifs in their genomic RNAs. He further found that these structural motifs are clustered with lineage specificity. This discovery provided fresh insights to the sequences, structures, functions, and druggable targets of coronaviruses, including the current pandemic SARS-CoV-2.

Dr. Chiou is committed to the discussion of the molecular mechanism of stem cells and the innovation and development of regenerative medicine. In recent years, he has successfully cooperated with internationally renowned basic research centers and top stem cell clinical teams through transnational and transnational fields (UCSD, UCLA, Kyoto University Hospital, Japan, The international cooperation of the Japan Institute of Physics and Chemistry (RIKEN), etc.) has accelerated the development of innovative medical technology and a personalized medical platform for the retina, with a view to implementing scientific problems as a starting point to solve major human health diseases such as retinopathy.

Dr. Shuen-Iu Hung has worked on pharmacogenomics, immunogenomics, and precision medicine for over 20 years. She has been interested in exploring the genomics and immune mechanism of drug hypersensitivity, particularly severe cutaneous adverse reactions (SCAR). She led a research team to discover the genetic markers, biomarker granulysin, and T cell receptors of SCAR caused by different drugs. Recently, Dr. Hung extended her work to develop neoantigen-based cell therapy against cancer. She works on the immune synapse composed of HLA, neoantigens, and T-cell receptor for developing precision immune cell therapy. Some studies of Dr. Hung have been successfully translated into clinical applications and have shown essential impacts.

Dr. Shu-Jen Chen received her Ph.D. degree in Biochemistry from Virginia Commonwealth University, did her Postdoctoral training at Baylor College of Medicine, and was a Research Assistant Professor at SUNY Buffalo. She joined National Health Research Institute (NHRI) as an Assistant Investigator and established the high throughput screening program for the institute. As one of the founding scientists, Dr. Chen joined TaiGen Biotechnology in 2001 to lead the in vitro pharmacology group. In 2006, she moved to Chang Gung University as an Associate Professor of the Department of Biomedical Sciences. As a co-founder of ACT Genomics, Dr. Chen has served as the Chief Scientific Officer since 2014. Dr. Chen specializes in automated drug screening systems, genomics and transcriptomics technologies, omics data analysis and biological database integration. She is also familiar with cancer biology, system integration and database design. She currently leads the sequencing group and the bioinformatics group at ACT Genomics to implement cancer genome sequencing for research and clinical applications.

Dr. Shuo-Ming Ou is an Assistant Professor of National Yang Ming Chiao Tung University, Taiwan. Dr. Ou received his Ph.D degree in genetics from Institute of Clinical Medicine, National Yang Ming Chiao Tung University. Dr. Ou’ research interests are to focus on the acute kidney injury and chronic kidney disease and to analyze the clinical outcomes in this field by using the concepts of omics, artificial intelligence, basic studies and epidemiology.

Dr. Szu-Hua Pan is an Associate Professor of Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University. Dr. Pan received her Ph.D. degree from Graduate Institute of Life Sciences, National Defense Medical Center and had been involved mainly in lung cancer studies for the past 20 years since then and now has been focused on developing novel therapeutics or diagnostic techniques for human disease. Dr. Pan’s research interest focuses on exploring the regulation mechanism of cancer metastasis, tumor neovascularization, DNA repair, drug resistance and cardiovascular disease from the view point of omic-driven protein network. In addition, Dr. Pan and her colleagues also develop an integrative phenotypic-based drug screening platform; combined with chemical proteome and in silico pharmacokinetic model, they successfully identified several small molecules that can develop as novel therapeutics for lung cancer treatment.

Dr. Tai-Ming Ko aims at translating the promise of data-driven genomic medicine into clinical reality. He received B.S. and Ph.D. degree in National Taiwan University. Dr. Ko joined NCTU after conducting postdoctoral research at the IBMS of Academia Sinica and at the University of Chicago. He has received some awards including Academia Sinica Distinguished Postdoctoral Scholarship (2014-2015), Tsung-Ming Tu’s YOUNG INVESTIGATOR AWARD (2018), YOUNG INVESTIGATOR AWARD of The 12th International Kawasaki Disease Symposium in Japan (2018), NCTU Bio-ICT Junior Chair Professor, (2018-2022), JCA-CHAAO Award (Category: Cancer research using artificial intelligence technologies on the frontiers of medical science), Japanese Cancer Association (2019), selected member of the Clinical Translational Research Network (CTRN), 10x Genomics, USA (2021). Currently, his lab at NYCU and IBMS (Academia Sinica) have early access to single-cell multi-omics technologies (scRNA-seq, scATAC-seq, scDNA-seq, CITE-seq, scVDJ-seq, and other advanced single-cell platforms) and integrative single-cell data analysis to better understand genomic molecular insights of highly heterogeneous cell populations in infectious diseases, vascular diseases, allergy, autoimmune diseases and cancer immunotherapy.

1. Clinical pediatric infectious diseases
2. Clinical virology
3. Vaccinology
4. Health policy
5. Hospital management

We study the communication of microorganisms and the bi-directional regulation between microbes and the host, especially gut. Specific probiotics are selected to regulate gut microbiota and to act as a target for disease therapeutics. We investigate the function of extracellular vesicles derived from probiotics and gut microbiota as well as their application on biomedicine and food science.

Dr. Yen-An Tang is a Research Scholar of Molecular Medicine Institute at the National Cheng Kung University (NCKU), Taiwan. Dr. Tang received his Ph.D degree from NCKU and have been working on tumor biology and genomic medicine for more than 10 years. Dr. Tang is devoted himself to identifying prognostic biomarkers in tumors, developing anti-cancer drugs, as well as disclosing the causative mutations leading to rare genetic disorders using both wet and dry labs approaches, such as whole exome sequencing (WES), and ChIP-seq. Dr. Tang is also an Assistant Director of Center for Genomic Medicine (CGM) in NCKU, in which his role is to supervise the tests conducting in CGM for genetic testing in reproductive precision medicine, and the AI-powered medical software devise belonging to Computer Aided Diagnosis, CADx.

Dr. Ying-Lan Chen aims to integrate the LC-MS/MS-based omics technologies, including proteomics, peptideomics and metabolomics analysis to reveal the peptide signaling pathways and regulatory mechanism of plant-nematode interaction. Dr. Chen discovered a group of evolutionarily conserved long-distance migrating peptides that can regulate the lignin biosynthesis and plant immunity and further facilitate the development of new biotechnological approach for nematode control.

Dr. Yi-Ping Hsueh has a long-term interest in exploring how genes control neuronal morphology and activity and thereby regulate neural circuit formation and behaviors. She has been focusing on causative genes for autism spectrum disorders (ASD) because ASD arise from aberrant neural development, resulting in abnormal neural connectivity. Emerging evidence indicates that causative genes for ASD may exhibit evolutionarily conserved functions in controlling neural connectivity in human and rodents. Those conserved mechanisms have encouraged her to target autism mouse models to illustrate how ASD-causative genes control neuronal development and connectivity and, consequently, regulate social interaction and other typical autism-related behaviors. Her research addresses critical and fundamental issues in neuroscience and also provides important insights into ASD.

Dr. Yi-Ting Chen joined Molecular Medicine Research Center at Chang Gung University (CGU) since 2007. Being a faculty member in the Department of Biomedical Sciences of CGU since 2013, Dr. Chen’s research has been dedicated to the development of targeted and untargeted proteomic and metabolomic platforms for clinical applications, primarily based on mass spectrometry. The laboratory is interested in research directed toward disease biomarker discovery using clinical human tissues, body fluids and associated cell models. The laboratory is also involved in various collaborations with chemical and biomedical researchers as well as clinical physicians (oncologists, urologists, pediatrician, and obstetrician) at the internal and international levels. She is also the elected council members of Taiwan Society for Mass Spectrometry and Taiwan Society for Proteomics.

Prof. Li, one of the top 2% scientists in the world, is a pioneer of artificial intelligence in medicine and translational biomedical informatics. He has devoted himself to evolving the next generation of Al in patient safety and prevention ("Earlier Medicine"). He has also been deeply involved in international collaborations for biomedical informatics development in Asia, America, Europe, and Africa.

He is currently President of the International Medical Informatics Association (IMIA) and previously served as Vice President of IMIA and President of the Asia-Pacific Association for Medical Informatics. In addition, he has been elected as a fellow of the Australian College of Health Informatics in 2009, the American College of Medical Informatics in 2010, and the International Academy of Health Science Informatics in 2017.

Dr. Yu-Wei Wu is an associate professor of the Graduate Institute of Biomedical Informatics at Taipei Medical University, Taiwan. Dr. Wu received his Ph.D. degree from School of Informatics and Computing at Indiana University. He then went to the Joint Bioenergy Institute at the Lawrence Berkeley National Laboratory to work as a postdoctoral research fellow before he came back to Taiwan. He has been working on resolving metagenomic problems using machine learning algorithms for more than 10 years. After joining Taipei Medical University he was also attempting to tackle the problem of predicting antimicrobial resistance activities for prokaryotic pathogens. His research interests include computational metagenomics, bioinformatics, machine learning, and anything related to prokaryotes.